AstraZeneca boosts oncology portfolio in Japan with Daiichi denosumab deal
This article was originally published in Scrip
Executive Summary
AstraZeneca has entered into a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis.